Aim: This observational follow-up study was designed to assess the long-term behavioural and clinical effects of receiving personal genetic risk information. The information disclosed was the carrier status of the apolipoprotein E (APOE)alleles, which differentially contribute to the genetic risk for cardiovascular disease (CVD) and Alzheimer’s disease. Methods: This study forms a continuum with a previous 1-year intervention (2010–2011) monitoring the effects of disclosing the carrier status of the APOE ε4 risk allele. The follow-up measurements, performed 5.5 years post-intervention, included clinical measurements (blood values and anthropomorphic parameters) and questionnaires (psychological and behavioural factors). The participants were healthy adult volunteers, aged 26–73 years (n = 70) who had participated in the previous intervention, and received their APOE allele status either at the beginning (former test group) or the end of the intervention (former control group). Results: Personal genetic risk information resulted in a moderate health-conscious change in diet and had a slight positive long-term effect on clinical factors, particularly the serum lipids. These improvements were subsequent to the disclosure of genetic information and occurred mainly in the APOE ε4-positive members of the former control group, that is, those who were at increased genetic risk for CVD but had not been informed of their status before the end of the intervention. In contrast, changes in the values and health behaviour of the APOE ε4-positive individuals in the former test group, who had already changed their health behaviour during the previous intervention as a result of being informed of their carrier status, varied more: some continued to improve, some remained at their previously improved level, and some relapsed slightly. Both groups had nonetheless displayed an improvement immediately subsequent to the disclosure of their personal genetic risk. Conclusion: Receiving information on increased personal genetic risk (carrier status of APOE ε4)for CVD provided the motivation for improvements in health behaviour. The resulting changes, while modest, in most cases remained visible even after a number of years.

1.
Borodulin
K
,
Vartiainen
E
,
Peltonen
M
,
Jousilahti
P
,
Juolevi
A
,
Laatikainen
T
, et al
Forty-year trends in cardiovascular risk factors in Finland
.
Eur J Public Health
.
2015
Jun
;
25
(
3
):
539
46
.
[PubMed]
1101-1262
2.
Salomaa
V
.
Genetic and Environmental Contributions to Cardiovascular Risk: Lessons From North Karelia and FINRISK
.
Glob Heart
.
2016
Jun
;
11
(
2
):
229
33
.
[PubMed]
2211-8160
3.
Ganesh
SK
,
Arnett
DK
,
Assimes
TL
,
Basson
CT
,
Chakravarti
A
,
Ellinor
PT
, et al;
American Heart Association Council on Functional Genomics and Translational Biology
;
American Heart Association Council on Epidemiology and Prevention
;
American Heart Association Council on Basic Cardiovascular Sciences
;
American Heart Association Council on Cardiovascular Disease in the Young
;
American Heart Association Council on Cardiovascular and Stroke Nursing
;
American Heart Association Stroke Council
.
Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association
.
Circulation
.
2013
Dec
;
128
(
25
):
2813
51
.
[PubMed]
0009-7322
4.
Smith
TW
,
Orleans
CT
,
Jenkins
CD
.
Prevention and health promotion: decades of progress, new challenges, and an emerging agenda
.
Health Psychol
.
2004
Mar
;
23
(
2
):
126
31
.
[PubMed]
0278-6133
5.
Schnohr
P
,
O’Keefe
JH
,
Lange
P
,
Jensen
GB
,
Marott
JL
.
Impact of persistence and non-persistence in leisure time physical activity on coronary heart disease and all-cause mortality: The Copenhagen City Heart Study
.
Eur J Prev Cardiol
.
2017
Oct
;
24
(
15
):
1615
23
.
[PubMed]
2047-4873
6.
Sheridan
SL
,
Viera
AJ
,
Krantz
MJ
,
Ice
CL
,
Steinman
LE
,
Peters
KE
, et al;
Cardiovascular Health Intervention Research and Translation Network Work Group on Global Coronary Heart Disease Risk
.
The effect of giving global coronary risk information to adults: a systematic review
.
Arch Intern Med
.
2010
Feb
;
170
(
3
):
230
9
.
[PubMed]
0003-9926
7.
Parker
C
.
Disclosing Information about the Risk of Inherited Disease
.
AMA J Ethics
.
2015
Sep
;
17
(
9
):
819
25
.
[PubMed]
2376-6980
8.
Liu
CC
,
Liu
CC
,
Kanekiyo
T
,
Xu
H
,
Bu
G
.
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
.
Nat Rev Neurol
.
2013
Feb
;
9
(
2
):
106
18
.
[PubMed]
1759-4758
9.
Mahley
RW
.
Central Nervous System Lipoproteins - Highlights
.
Arterioscler Thromb Vasc Biol
.
2016
;
36
(
7
):
1305
15
.
[PubMed]
1079-5642
10.
Tudorache
IF
,
Trusca
VG
,
Gafencu
AV
,
Apolipoprotein
E
.
Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features
.
Comput Struct Biotechnol J
.
2017
Jun
;
15
:
359
65
.
[PubMed]
2001-0370
11.
Theendakara
V
,
Peters-Libeu
CA
,
Spilman
P
,
Poksay
KS
,
Bredesen
DE
,
Rao
RV
.
Direct Transcriptional Effects of Apolipoprotein E
.
J Neurosci
.
2016
Jan
;
36
(
3
):
685
700
.
[PubMed]
0270-6474
12.
Minihane
AM
,
Jofre-Monseny
L
,
Olano-Martin
E
,
Rimbach
G
.
ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation
.
Proc Nutr Soc
.
2007
May
;
66
(
2
):
183
97
.
[PubMed]
0029-6651
13.
Lovegrove
JA
,
Gitau
R
.
Personalized nutrition for the prevention of cardiovascular disease: a future perspective
.
J Hum Nutr Diet
.
2008
Aug
;
21
(
4
):
306
16
.
[PubMed]
0952-3871
14.
Masson
LF
,
McNeill
G
,
Avenell
A
.
Genetic variation and the lipid response to dietary intervention: a systematic review
.
Am J Clin Nutr
.
2003
May
;
77
(
5
):
1098
111
.
[PubMed]
0002-9165
15.
Corbo
RM
,
Scacchi
R
,
Apolipoprotein
E
.
Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele?
Ann Hum Genet
.
1999
Jul
;
63
(
Pt 4
):
301
10
.
[PubMed]
0003-4800
16.
Poirier
J
,
Miron
J
,
Picard
C
,
Gormley
P
,
Théroux
L
,
Breitner
J
, et al
Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer’s disease
.
Neurobiol Aging
.
2014
Sep
;
35
Suppl 2
:
S3
10
.
[PubMed]
0197-4580
17.
Tai
LM
,
Thomas
R
,
Marottoli
FM
,
Koster
KP
,
Kanekiyo
T
,
Morris
AW
, et al
The role of APOE in cerebrovascular dysfunction
.
Acta Neuropathol
.
2016
May
;
131
(
5
):
709
23
.
[PubMed]
0001-6322
18.
Song
Y
,
Stampfer
MJ
,
Liu
S
.:
Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease.
Ann Intern Med
2004
[cited 2013 Oct 9];141:137–47.
19.
Carvalho-Wells
AL
,
Jackson
KG
,
Lockyer
S
,
Lovegrove
JA
,
Minihane
AM
.
APOE genotype influences triglyceride and C-reactive protein responses to altered dietary fat intake in UK adults
.
Am J Clin Nutr
.
2012
Dec
;
96
(
6
):
1447
53
.
[PubMed]
0002-9165
20.
Gultom
LC
,
Sjarif
DR
,
Sudoyo
HA
,
Mansyur
M
,
Hadinegoro
SR
,
Immanuel
S
, et al
The role of apolipoprotein E polymorphism in improving dyslipidemia in obese adolescents following physical exercise and National Cholesterol Education Program Step II intervention
.
J Pediatr Endocrinol Metab
.
2015
May
;
28
(
5-6
):
597
603
.
[PubMed]
0334-018X
21.
Hietaranta-Luoma
HL
,
Luomala
HT
,
Puolijoki
H
,
Hopia
A
.
Using ApoE Genotyping to Promote Healthy Lifestyles in Finland - Psycholoical Impacts: Randomized Controlled Trial
.
J Genet Counsel
;
2015
.
22.
Hietaranta-Luoma
HL
,
Tahvonen
R
,
Iso-Touru
T
,
Puolijoki
H
,
Hopia
A
.
An intervention study of individual, apoE genotype-based dietary and physical-activity advice: impact on health behavior
.
J Nutrigenet Nutrigenomics
.
2014
;
7
(
3
):
161
74
.
[PubMed]
1661-6499
23.
Hietaranta-Luoma
HL
,
Luomala
HT
,
Tahvonen
R
,
Puolijoki
H
,
Koivusilta
L
,
Hopia
A
.
Using Individual, ApoE Genotype-Based Dietary and Physical Activity Advice to Promote a Healthy Lifestyle: Associations between Psychological, Behavioral and Clinical Factors
.
J Nutrit Health Food Sci
.
2015
;
3
(
4
):
1
7
. 2372-0980
24.
Hietaranta-Luoma
HL
,
Åkerman
K
,
Tahvonen
R
,
Puolijoki
H
,
Hopia
A
.
Using Individual, ApoE Genotype-Based Dietary and Physical Activity Advice to Promote Healthy Lifestyles in Finland—Impacts on Cardiovascular Risk Markers
.
Open J Prev Med
.
2015
;
5
(
05
):
206
17
. 2162-2477
25.
Helakorpi
S
,
Prättälä
R
,
Uutela
A
. Health Behaviour and Health among the Finnish Adult Population, Spring 2007. Helsinki,
2008
. Available from: www.thl.fi
26.
Finnish Heart Association
.
Diet Fat Quality test
.
2010
. Available from: http://www.sydanliitto.fi/etusivu
27.
Stelmach-Mardas
M
,
Kleiser
C
,
Uzhova
I
,
Peñalvo
JL
,
La Torre
G
,
Palys
W
, et al
Seasonality of food groups and total energy intake: a systematic review and meta-analysis
.
Eur J Clin Nutr
.
2016
Jun
;
70
(
6
):
700
8
.
[PubMed]
0954-3007
28.
McCarney
R
,
Warner
J
,
Iliffe
S
,
van Haselen
R
,
Griffin
M
,
Fisher
P
.
The Hawthorne Effect: a randomised, controlled trial
.
BMC Med Res Methodol
.
2007
Jul
;
7
(
1
):
30
.
[PubMed]
1471-2288
29.
Vepsäläinen
S
,
Helisalmi
S
,
Koivisto
AM
,
Tapaninen
T
,
Hiltunen
M
,
Soininen
H
.
Somatostatin genetic variants modify the risk for Alzheimer’s disease among Finnish patients
.
J Neurol
.
2007
Nov
;
254
(
11
):
1504
8
.
[PubMed]
0340-5354
30.
Knowles
JW
,
Zarafshar
S
,
Pavlovic
A
,
Goldstein
BA
,
Tsai
S
,
Li
J
, et al
Impact of a Genetic Risk Score for Coronary Artery Disease on Reducing Cardiovascular Risk: A Pilot Randomized Controlled Study
.
Front Cardiovasc Med
.
2017
Aug
;
4
:
53
.
[PubMed]
2297-055X
31.
Celis-Morales
C
,
Livingstone
KM
,
Marsaux
CF
,
Macready
AL
,
Fallaize
R
,
O’Donovan
CB
, et al;
Food4Me Study
.
Effect of personalized nutrition on health-related behaviour change: evidence from the Food4Me European randomized controlled trial
.
Int J Epidemiol
.
2017
Apr
;
46
(
2
):
578
88
.
[PubMed]
1464-3685
32.
Chao
S
,
Roberts
JS
,
Marteau
TM
,
Silliman
R
,
Cupples
LA
,
Green
RC
.
Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study
.
Alzheimer Dis Assoc Disord
.
2008
Jan-Mar
;
22
(
1
):
94
7
.
[PubMed]
0893-0341
33.
Nielsen
DE
,
El-Sohemy
A
.
Disclosure of genetic information and change in dietary intake: a randomized controlled trial
.
PLoS One
.
2014
Nov
;
9
(
11
):
e112665
.
[PubMed]
1932-6203
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.